

About HOPE-Neuron Therapeutx

HOPE-Neuron Therapeutx is a leading innovator in device-enabled, cell-based therapeutics for the treatment of autoimmune neurodegenerative diseases such as ALS (Amyotrophic Lateral Sclerosis), Parkinson's, and MS (multiple sclerosis). Our mission is to bring safe, effective, and accessible therapies to patients by reprogramming immune responses at the intersection of neurology and immunology.

Built on decades of research, HOPE-Neuron's patented non-pharma technology (SElanetx™) activates the body's own immune system to fight disease through immune balancing and healing, anti-inflammation, and the normalization of imbalanced disease cells. Designed as an outpatient therapy utilizing a patient's own blood, SELanetx™ represents a new type of therapy platform for multiple conditions. We are currently advancing through preclinical and early-stage clinical development, with a goal to initiate human trials within 12 months of funding. Our regulatory strategy includes fast-track designation and a clear path to FDA engagement.

HOPE-Neuron is based in the United States and is committed to improving the lives of patients through innovative science, ethical development, and long-term value creation.

For investor inquiries, media requests, or partnership opportunities, please contact:
mforney@hopeneuron.com